A Hodgkin-kór kezelése

Translated title of the contribution: Current therapy of Hodgkin's disease

A. Rosta, Z. Molnár, T. Schneider, E. Várady, B. Deák, O. Ésik

Research output: Contribution to journalArticle

Abstract

Hodgkin's disease is a clonal B-cell disease. The exact etiology of the disease has not yet been identified, research data showing the crucial role of the Epstein-Barr virus. The Hodgkin's disease is curable in 70-80 % of the cases. In the early stage of the disease, the treatment of choice should be the combined modality therapy. The required number of cycles of combined chemotherapy, the dose and the field extension of radiotherapy are all subjects of recent clinical trials. In the advanced stage of Hodgkin's disease more (6-8) cycles of combined chemotherapy and, if necessary, radiotherapy of the affected field is the treatment of choice. In advanced Hodgkin's disease with unfavourable prognosis, the role of higher dose-intensity and the combination of more potent chemotherapeutic agents are evaluated in clinical trials, with special consideration to the danger of late toxicity (BEACOPP, Stanford V protocol). In the treatment of early (within 1 year) chemosensitive relapses of Hodgkin's disease, high-dose chemotherapy with autologous peripheral stem cell transplantation has improved therapeutic results. Current results of advanced cases with unfavourable prognosis, of primary progressive and resistant disease, relapsing Hodgkin's disease and the treatment of elderly patients are yet unsatisfactory. The main trends of recent research are: development of new potent chemotherapeutic agents, application of allogeneous "mini" transplantation (graft versus Hodgkin's disease effect) and the therapeutic use of mono or bispecific monoclonal antibodies. It is desirable, that primary, secondary and further treatments of Hodgkin's disease are performed in specific hematological or oncological centers where necessary experience of complex treatment is available, as well as the application of aggressive treatment methods, modern radiotherapy and also the facilities for handling unwanted complications.

Original languageHungarian
Pages (from-to)412-417
Number of pages6
JournalLege Artis Medicinae
Volume11
Issue number6-7
Publication statusPublished - 2001

Fingerprint

Hodgkin Disease
Radiotherapy
Therapeutics
Drug Therapy
Clinical Trials
Bispecific Antibodies
Peripheral Blood Stem Cell Transplantation
Combined Modality Therapy
Therapeutic Uses
Human Herpesvirus 4
Research
B-Lymphocytes
Transplantation
Transplants
Recurrence

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Rosta, A., Molnár, Z., Schneider, T., Várady, E., Deák, B., & Ésik, O. (2001). A Hodgkin-kór kezelése. Lege Artis Medicinae, 11(6-7), 412-417.

A Hodgkin-kór kezelése. / Rosta, A.; Molnár, Z.; Schneider, T.; Várady, E.; Deák, B.; Ésik, O.

In: Lege Artis Medicinae, Vol. 11, No. 6-7, 2001, p. 412-417.

Research output: Contribution to journalArticle

Rosta, A, Molnár, Z, Schneider, T, Várady, E, Deák, B & Ésik, O 2001, 'A Hodgkin-kór kezelése', Lege Artis Medicinae, vol. 11, no. 6-7, pp. 412-417.
Rosta A, Molnár Z, Schneider T, Várady E, Deák B, Ésik O. A Hodgkin-kór kezelése. Lege Artis Medicinae. 2001;11(6-7):412-417.
Rosta, A. ; Molnár, Z. ; Schneider, T. ; Várady, E. ; Deák, B. ; Ésik, O. / A Hodgkin-kór kezelése. In: Lege Artis Medicinae. 2001 ; Vol. 11, No. 6-7. pp. 412-417.
@article{39bcc26e5e2a4b3ca4aff0de1c1b1710,
title = "A Hodgkin-k{\'o}r kezel{\'e}se",
abstract = "Hodgkin's disease is a clonal B-cell disease. The exact etiology of the disease has not yet been identified, research data showing the crucial role of the Epstein-Barr virus. The Hodgkin's disease is curable in 70-80 {\%} of the cases. In the early stage of the disease, the treatment of choice should be the combined modality therapy. The required number of cycles of combined chemotherapy, the dose and the field extension of radiotherapy are all subjects of recent clinical trials. In the advanced stage of Hodgkin's disease more (6-8) cycles of combined chemotherapy and, if necessary, radiotherapy of the affected field is the treatment of choice. In advanced Hodgkin's disease with unfavourable prognosis, the role of higher dose-intensity and the combination of more potent chemotherapeutic agents are evaluated in clinical trials, with special consideration to the danger of late toxicity (BEACOPP, Stanford V protocol). In the treatment of early (within 1 year) chemosensitive relapses of Hodgkin's disease, high-dose chemotherapy with autologous peripheral stem cell transplantation has improved therapeutic results. Current results of advanced cases with unfavourable prognosis, of primary progressive and resistant disease, relapsing Hodgkin's disease and the treatment of elderly patients are yet unsatisfactory. The main trends of recent research are: development of new potent chemotherapeutic agents, application of allogeneous {"}mini{"} transplantation (graft versus Hodgkin's disease effect) and the therapeutic use of mono or bispecific monoclonal antibodies. It is desirable, that primary, secondary and further treatments of Hodgkin's disease are performed in specific hematological or oncological centers where necessary experience of complex treatment is available, as well as the application of aggressive treatment methods, modern radiotherapy and also the facilities for handling unwanted complications.",
keywords = "Advanced stage Hodgkin's disease, Combined chemotherapy, Combined modality therapy, Early stage Hodgkin's disease, Second line treatment",
author = "A. Rosta and Z. Moln{\'a}r and T. Schneider and E. V{\'a}rady and B. De{\'a}k and O. {\'E}sik",
year = "2001",
language = "Hungarian",
volume = "11",
pages = "412--417",
journal = "Lege Artis Medicinae",
issn = "0866-4811",
publisher = "Literatura Medica Publishing House",
number = "6-7",

}

TY - JOUR

T1 - A Hodgkin-kór kezelése

AU - Rosta, A.

AU - Molnár, Z.

AU - Schneider, T.

AU - Várady, E.

AU - Deák, B.

AU - Ésik, O.

PY - 2001

Y1 - 2001

N2 - Hodgkin's disease is a clonal B-cell disease. The exact etiology of the disease has not yet been identified, research data showing the crucial role of the Epstein-Barr virus. The Hodgkin's disease is curable in 70-80 % of the cases. In the early stage of the disease, the treatment of choice should be the combined modality therapy. The required number of cycles of combined chemotherapy, the dose and the field extension of radiotherapy are all subjects of recent clinical trials. In the advanced stage of Hodgkin's disease more (6-8) cycles of combined chemotherapy and, if necessary, radiotherapy of the affected field is the treatment of choice. In advanced Hodgkin's disease with unfavourable prognosis, the role of higher dose-intensity and the combination of more potent chemotherapeutic agents are evaluated in clinical trials, with special consideration to the danger of late toxicity (BEACOPP, Stanford V protocol). In the treatment of early (within 1 year) chemosensitive relapses of Hodgkin's disease, high-dose chemotherapy with autologous peripheral stem cell transplantation has improved therapeutic results. Current results of advanced cases with unfavourable prognosis, of primary progressive and resistant disease, relapsing Hodgkin's disease and the treatment of elderly patients are yet unsatisfactory. The main trends of recent research are: development of new potent chemotherapeutic agents, application of allogeneous "mini" transplantation (graft versus Hodgkin's disease effect) and the therapeutic use of mono or bispecific monoclonal antibodies. It is desirable, that primary, secondary and further treatments of Hodgkin's disease are performed in specific hematological or oncological centers where necessary experience of complex treatment is available, as well as the application of aggressive treatment methods, modern radiotherapy and also the facilities for handling unwanted complications.

AB - Hodgkin's disease is a clonal B-cell disease. The exact etiology of the disease has not yet been identified, research data showing the crucial role of the Epstein-Barr virus. The Hodgkin's disease is curable in 70-80 % of the cases. In the early stage of the disease, the treatment of choice should be the combined modality therapy. The required number of cycles of combined chemotherapy, the dose and the field extension of radiotherapy are all subjects of recent clinical trials. In the advanced stage of Hodgkin's disease more (6-8) cycles of combined chemotherapy and, if necessary, radiotherapy of the affected field is the treatment of choice. In advanced Hodgkin's disease with unfavourable prognosis, the role of higher dose-intensity and the combination of more potent chemotherapeutic agents are evaluated in clinical trials, with special consideration to the danger of late toxicity (BEACOPP, Stanford V protocol). In the treatment of early (within 1 year) chemosensitive relapses of Hodgkin's disease, high-dose chemotherapy with autologous peripheral stem cell transplantation has improved therapeutic results. Current results of advanced cases with unfavourable prognosis, of primary progressive and resistant disease, relapsing Hodgkin's disease and the treatment of elderly patients are yet unsatisfactory. The main trends of recent research are: development of new potent chemotherapeutic agents, application of allogeneous "mini" transplantation (graft versus Hodgkin's disease effect) and the therapeutic use of mono or bispecific monoclonal antibodies. It is desirable, that primary, secondary and further treatments of Hodgkin's disease are performed in specific hematological or oncological centers where necessary experience of complex treatment is available, as well as the application of aggressive treatment methods, modern radiotherapy and also the facilities for handling unwanted complications.

KW - Advanced stage Hodgkin's disease

KW - Combined chemotherapy

KW - Combined modality therapy

KW - Early stage Hodgkin's disease

KW - Second line treatment

UR - http://www.scopus.com/inward/record.url?scp=0034878723&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034878723&partnerID=8YFLogxK

M3 - Article

VL - 11

SP - 412

EP - 417

JO - Lege Artis Medicinae

JF - Lege Artis Medicinae

SN - 0866-4811

IS - 6-7

ER -